Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Which prostate cancer drug is easier on patients? new study aims to find out

NCT ID NCT06173362

First seen Mar 25, 2026 · Last updated Jun 15, 2026 · Updated 18 times

Summary

This study compares the side effects of two standard treatments for advanced prostate cancer: abiraterone plus prednisone versus darolutamide alone. Researchers want to see which drug causes fewer severe side effects in 75 adult patients. The goal is to help doctors choose the treatment that is easier for patients to tolerate.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for STAGE IV PROSTATE CANCER AJCC V8 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of California Davis Comprehensive Cancer Center

    RECRUITING

    Sacramento, California, 95817, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.